338 related articles for article (PubMed ID: 9819404)
21. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia.
Lutterbach B; Westendorf JJ; Linggi B; Isaac S; Seto E; Hiebert SW
J Biol Chem; 2000 Jan; 275(1):651-6. PubMed ID: 10617663
[TBL] [Abstract][Full Text] [Related]
22. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.
Chevallier N; Corcoran CM; Lennon C; Hyjek E; Chadburn A; Bardwell VJ; Licht JD; Melnick A
Blood; 2004 Feb; 103(4):1454-63. PubMed ID: 14551142
[TBL] [Abstract][Full Text] [Related]
23. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
Fenrick R; Amann JM; Lutterbach B; Wang L; Westendorf JJ; Downing JR; Hiebert SW
Mol Cell Biol; 1999 Oct; 19(10):6566-74. PubMed ID: 10490596
[TBL] [Abstract][Full Text] [Related]
24. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
25. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
26. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
27. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
28. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
29. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
Lenny N; Meyers S; Hiebert SW
Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
[TBL] [Abstract][Full Text] [Related]
30. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
31. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
32. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.
Zhang Y; Strissel P; Strick R; Chen J; Nucifora G; Le Beau MM; Larson RA; Rowley JD
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3070-5. PubMed ID: 11867721
[TBL] [Abstract][Full Text] [Related]
33. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor.
Lutterbach B; Hou Y; Durst KL; Hiebert SW
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12822-7. PubMed ID: 10536006
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic consequences of AML1-ETO action at the human c-FMS locus.
Follows GA; Tagoh H; Lefevre P; Hodge D; Morgan GJ; Bonifer C
EMBO J; 2003 Jun; 22(11):2798-809. PubMed ID: 12773394
[TBL] [Abstract][Full Text] [Related]
35. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
36. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
38. Oligomerization of ETO is obligatory for corepressor interaction.
Zhang J; Hug BA; Huang EY; Chen CW; Gelmetti V; Maccarana M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 2001 Jan; 21(1):156-63. PubMed ID: 11113190
[TBL] [Abstract][Full Text] [Related]
39. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
40. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]